{
  "trial_id": "NCT02364297",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Patients developing acute variceal bleeding from GOV2 and/or IGV1 defined according to Baveno II criteria, admitted in the Hospital and receiving standard combined medical therapy (somatostatin 3 mg/12h continuous IV infusion or terlipressin, 2mg/4h IV + endoscopic injection of tissue adhesives as per center protocol).",
      "label": "met"
    },
    {
      "criterion": "Terminal liver disease (bilirrubin > 10 mg/dL and/or prothrombin index < 30%); or other fatal non-liver diseases.",
      "label": "met"
    },
    {
      "criterion": "Denied informed consent.",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Hepatocarcinoma without therapeutic options (according to Milan criteria).",
      "label": "triggers"
    },
    {
      "criterion": "Portal or mesenteric vein thrombosis avoiding the performance of TIPS.",
      "label": "unknown"
    },
    {
      "criterion": "Acute alcoholic hepatitis.",
      "label": "unknown"
    }
  ],
  "notes": "Patient has HCV Cirrhosis, grade II esophageal varices, and recent admission for UGIB. He is being treated with lactulose for hepatic encephalopathy.",
  "_meta": {
    "topic_id": "7",
    "trial_id": "NCT02364297",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}